• Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

COPD Insights for Primary Care: 5 New Studies

Slideshow

Findings: Don’t blame patients for all inhaler-use errors; singing may help improve breathing, QOL; Rx adherence does improve over time; plus 3 more outcomes of interest.

Related Videos
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Related Content
Direct Mail to Older Adults at Risk for Pneumococcal Disease Improves Vaccination Rates / image credit ©Kateryna_Kon/stock.adobe.com

Direct Mail to Older Adults at Risk for Pneumococcal Disease Improves Vaccination Rates

Grace Halsey
April 2nd 2025
Article

A mail campaign targeting adults with chronic conditions as well as their GPs increased the number receiving at least 1 shot by 9.5 percentage points.

Respiratory Tripledemic 2022-23: An Expert Recap

Respiratory Tripledemic 2022-23: An Expert Recap

Sydney Jennings
April 6th 2023
Podcast

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

Omlyclo Gains FDA Approval as Interchangeable Omalizumab Biosimilar: Daily Dose / image credit: ©New Africa/AdobeStock

Omlyclo Gains FDA Approval as Interchangeable Omalizumab Biosimilar: Daily Dose

Sydney Jennings
March 24th 2025
Article

Your daily dose of the clinical news you may have missed.

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

Sydney Jennings
May 20th 2022
Podcast

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

FDA Approves Omlyclo as First Interchangeable Omalizumab Biosimilar

FDA Approves Omlyclo as First Interchangeable Omalizumab Biosimilar

Patient Care Editorial Staff
March 10th 2025
Article

Omlyclo is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.

Dupilumab Shows Efficacy and Safety in COPD With Type 2 Inflammation: AAAAI 2025

Dupilumab Shows Efficacy and Safety in COPD With Type 2 Inflammation: AAAAI 2025

Patient Care Editorial Staff
March 6th 2025
Article

Investigators concluded that dupilumab reduced exacerbation rates, improved lung function, and decreased systemic corticosteroid use in patients with COPD driven by type 2 inflammation.

© 2025 MJH Life Sciences

All rights reserved.